Non-Alcoholic Fatty Liver Disease • NAFLD • Hepatic Steatosis • NASH • MASLD

Hepatic steatosis and NAFLD are the same finding. The cause is not always what the workup is looking for. The stage you are in right now may still be the one that can heal.

What it is

Non-alcoholic fatty liver disease — NAFLD — is a condition in which fat accumulates in liver tissue in people who drink little or no alcohol. It is the most common liver condition in the United States, affecting an estimated 24 to 30 percent of the adult population.

If your clinical notes contain the words hepatic steatosis — that is NAFLD. They are the same finding described in different language. Hepatic steatosis is the technical term for fat accumulation in liver cells. NAFLD is the clinical label applied to that finding in a non-drinking patient. If nobody connected those two terms for you, that gap ends here.

NAFLD exists on a spectrum. Understanding where you are on that spectrum matters because the stages do not all carry the same prognosis — and they do not all have the same path forward.

The progression — and why the stage you are in right now matters:

Hepatic steatosis — fat in the liver — can heal. Remove the upstream cause, reduce the fat load on the liver, and liver tissue can recover. This is the window. This is the stage where intervention changes the trajectory.

Non-alcoholic steatohepatitis — NASH — is the next stage. Fat accumulation is now accompanied by active inflammation and liver cell injury. NASH carries meaningful risk of progression to fibrosis. Some NASH can still be improved with aggressive intervention, but the window is narrowing.

Fibrosis is scarring. Once liver tissue scars, that damage does not reverse. The liver loses functional capacity permanently in those areas. The medical term for end-stage liver scarring is cirrhosis — and cirrhosis does not heal. Management at that stage is about slowing further damage and managing complications, not recovery.

The distance between hepatic steatosis and fibrosis is not fixed. Some people progress slowly over decades. Some progress faster. The trajectory depends on the upstream cause, how long it continues unaddressed, and individual factors that are not fully predictable.

If your clinical notes say hepatic steatosis — that is the window. That is the finding that still has a recoverable path forward. The question worth asking right now is what is causing it and whether that cause is being correctly identified.

The standard explanation for NAFLD in a non-drinking patient points to insulin resistance, excess carbohydrate intake, obesity, and metabolic syndrome. That explanation is frequently correct. It is not always complete.

What it is not

NAFLD is not:

• Caused by alcohol — by definition. Alcoholic fatty liver disease is a separate condition with a separate mechanism.

• Always caused by obesity — NAFLD occurs across the full weight spectrum. Lean NAFLD is a documented and underrecognized presentation.

• Always caused by insulin resistance — other upstream causes produce an identical picture on imaging and standard labwork.

• Always visible on standard liver enzyme testing — ALT and AST can be normal in the presence of significant hepatic steatosis. A normal liver enzyme panel does not rule out NAFLD.

• A single-cause condition — the liver accumulates fat through several distinct mechanisms. The standard workup identifies the most common one. It is not built to find all of them.

• Automatically permanent — hepatic steatosis can heal when the upstream cause is correctly identified and removed. Fibrosis and cirrhosis cannot. The stage matters.

Symptoms

NAFLD is frequently silent. Most people with simple steatosis have no symptoms at all and are diagnosed incidentally — on imaging ordered for another reason, or when mildly elevated liver enzymes appear on routine bloodwork.

When symptoms are present:

• Fatigue — often attributed to other causes

• Mild to moderate discomfort or a sense of fullness in the upper right abdomen — where the liver sits

• Enlarged liver on physical exam or imaging

With progression to NASH:

• More persistent fatigue

• Abdominal discomfort

• Elevated liver enzymes — ALT and AST — on bloodwork, though these can fluctuate and be normal even with active disease

With advanced fibrosis or cirrhosis:

• Jaundice — yellowing of skin and eyes

• Ascites — fluid accumulation in the abdomen

• Easy bruising and bleeding

• Confusion — hepatic encephalopathy in severe cases

The silent early phase is the dangerous one. By the time symptoms appear, the disease has often been progressing for years.

The cause the standard workup is not looking for

Imaging cannot tell you why fat is in the liver. Ultrasound, CT, and MRI can confirm that fat is present and estimate how much. They cannot tell you whether that fat got there because of insulin resistance, excess dietary fructose, alcohol, medication effect, or a genetic enzyme deficiency that prevents the liver from processing fructose at all.

The standard NAFLD workup in a non-drinking patient assumes insulin resistance and metabolic syndrome as the primary driver. That assumption is reasonable. It is not always correct.

Hereditary fructose intolerance — HFI — produces NAFLD through a completely different mechanism. The Aldolase B enzyme deficiency causes fructose-1-phosphate to accumulate in liver cells rather than being processed. That accumulated substrate drives fat production and liver damage directly — independent of insulin resistance, independent of overall caloric intake, independent of body weight.

HFI-driven NAFLD looks identical to insulin-resistance-driven NAFLD on every standard imaging study. The liver does not label its fat by cause. A patient with HFI and NAFLD will receive the same imaging report as a patient with metabolic syndrome and NAFLD. The standard workup will attribute the finding to the most common cause without testing for the less common one.

HFI Triad note: Elevated triglycerides, NAFLD, and reactive hypoglycemia can each appear as standalone findings — but when they cluster together, especially alongside a history of aversion to sweet foods or abdominal symptoms after fructose-containing meals, hereditary fructose intolerance is worth considering. These three findings are frequently one problem — a liver that cannot process fructose — expressing itself in three directions simultaneously. The standard NAFLD workup does not test for it. See the HFI page in the Metabolic & Genetic section of the Medical Library.

The rosacea connection

A 2017 study published in the Journal of the American Academy of Dermatology documented a statistically significant association between NAFLD and rosacea — a chronic skin condition involving facial redness, visible blood vessels, and in some cases pustular lesions across the cheeks and nose.

The mechanism is not fully established. The proposed connections involve shared inflammatory pathways, gut microbiome disruption, and the liver's role in processing the bacterial byproducts that may drive rosacea flares. The research is ongoing and the association does not establish causation.

What it does establish is that the liver's condition can express itself on the skin — and that a skin finding and a liver finding in the same patient may not be coincidental. If rosacea and NAFLD are both present, that combination is worth noting explicitly to your physician rather than treating them as two separate unrelated findings.

History

The term non-alcoholic fatty liver disease was coined in 1980 by Ludwig and colleagues at the Mayo Clinic, describing a group of patients whose liver biopsies showed changes identical to alcoholic liver disease despite little or no alcohol consumption. Before that, the condition existed but lacked a name — and without a name it was largely invisible as a clinical entity.

Recognition of NAFLD as a significant public health concern accelerated through the 1990s and 2000s as prevalence data accumulated. The parallel rise in NAFLD diagnoses with the rise in obesity, metabolic syndrome, and Type 2 diabetes confirmed the metabolic connection. The parallel rise with the widespread deployment of high-fructose corn syrup into the food supply beginning in the mid-1970s added a specific dietary dimension to the research — the fructose-triglyceride-NAFLD connection is biochemically documented, though the degree to which dietary fructose in the general population drives NAFLD independently of overall caloric excess remains debated.

In 2023, the field formally renamed NAFLD to MASLD — metabolic dysfunction-associated steatotic liver disease — to better reflect the metabolic underpinnings and reduce the stigma associated with the "non-alcoholic" framing. Many clinicians and patients still use NAFLD. Both terms refer to the same spectrum of disease.

What you can do about it

There is no FDA-approved medication specifically for NAFLD or NASH as of the time this page was written, though several are in late-stage clinical trials.

Management is primarily lifestyle-based with component-specific medication where indicated.

Dietary change: Reduction in fructose and added sugar intake has direct mechanistic support for NAFLD — the liver's fructose processing pathway is directly implicated in hepatic fat accumulation. This is independent of overall caloric reduction. Low carbohydrate approaches have shown benefit in clinical studies.

Weight reduction: A sustained loss of 7 to 10 percent of body weight has shown meaningful benefit for liver histology in NASH in clinical trials. This is the most consistently documented intervention for slowing progression.

Physical activity: Regular aerobic exercise improves liver fat content independently of weight loss. The mechanism involves improved insulin sensitivity and direct effects on hepatic fat metabolism.

Monitoring:

• Regular liver enzyme monitoring — ALT, AST, GGT

• Liver imaging — ultrasound as baseline, with follow-up as indicated

• FIB-4 score — a calculated index using age, liver enzymes, and platelet count that estimates fibrosis risk without biopsy

• Elastography — a non-invasive imaging method for assessing liver stiffness as a proxy for fibrosis

If standard interventions are not producing expected results: If dietary change, fructose reduction, and appropriate weight management are not improving the NAFLD picture — particularly if elevated triglycerides and reactive hypoglycemia are also present — the HFI differential is worth raising explicitly with your physician. See the HFI Testing page for the critical note on what tests are and are not safe to pursue.

Asking for the right test

NAFLD diagnosis and staging involve several tools, and the standard minimum is often insufficient for a complete picture.

Standard initial evaluation:

• Liver enzyme panel — ALT, AST, GGT, alkaline phosphatase

• Abdominal ultrasound — most common initial imaging, sensitive for moderate to severe steatosis, less sensitive for early or mild fat accumulation

• Fasting lipid panel including triglycerides

• Fasting blood glucose and HbA1c

For fuller staging:

• FIB-4 index — calculated from age, ALT, AST, platelet count. Estimates fibrosis risk. Can be calculated from standard bloodwork already in hand.

• Liver elastography — FibroScan or MR elastography — non-invasive assessment of liver stiffness

• MRI-PDFF — magnetic resonance imaging proton density fat fraction — most accurate non-invasive quantification of liver fat content

• Liver biopsy — still the gold standard for definitive staging of fibrosis and NASH, though increasingly reserved for cases where non-invasive staging is inconclusive

What the standard workup does not include: The standard NAFLD workup does not include ALDOB genetic sequencing. If the HFI triad is present — elevated triglycerides, NAFLD, and reactive hypoglycemia — ask your physician specifically about HFI as a differential before accepting that the standard workup has identified the complete cause. See the HFI Testing Critical Correction for what tests are and are not safe.

Personal note

NAFLD was named in my clinical notes after MRI scans during the 28-doctor loop — though the term used was hepatic steatosis. I had to backtrack the technical language to find out that hepatic steatosis and NAFLD are the same finding. That extra step should not be necessary. What nobody explained at the time is that hepatic steatosis — fat in the liver — is the stage that can still heal. Fibrosis, the scarring that comes next, largely cannot. If your notes say hepatic steatosis and nobody connected that word to a cause or a timeline, this page is for you.

The finding was documented. It was in the record. And nobody connected it to the triglyceride picture that was also in the record, in the same patient, at the same time.

I told every doctor exactly what I was eating. Gluten free. No alcohol. Meat, vegetables, occasional fruit. No processed food. No gluten free replacement products. I asked repeatedly why my triglycerides were skyrocketing. The answer I got was statins, which do not treat triglycerides. I had to fight for fenofibrate, which does. Nobody asked why a person eating a clean whole food diet with no alcohol was producing triglycerides at that level and showing fat accumulation on liver imaging simultaneously. Nobody put those two findings in the same room and asked what upstream cause could explain both of them at once.

The answer was HFI — a liver that could not process fructose, converting it to fat and releasing it as triglycerides. The occasional fruit and veggies was enough. It does not matter how clean the rest of the diet is. Fructose in any amount goes into a liver without functional Aldolase B and comes out as fat and triglycerides. The hepatic steatosis finding on the MRI and the triglyceride finding on the labwork were the same problem expressing itself in two directions. They were documented separately, treated separately, and never connected.

I also want to document a personal observation here — and I want to be clear this is personal observation only, not peer-reviewed, not a medical claim. I have noticed that on crash days and during metabolic stress periods, facial redness and skin changes present more prominently on the right cheek than the left. The liver sits on the right side of the body. The NAFLD-rosacea connection is documented in peer-reviewed literature. Whether there is any relationship between the laterality of my skin presentation and liver involvement on the same side — I cannot say. I am noting it as an observation worth documenting, not as a conclusion. If you have noticed something similar, it is worth mentioning to your physician rather than dismissing.

The piece I want to land clearly: hepatic steatosis in your clinical notes is not a complete answer. It is a description of what the imaging found. It is not an explanation of why. And it is the stage that can still heal — if the upstream cause is correctly identified and removed before scarring begins. The why has to be asked explicitly, and the standard workup is not designed to find every possible upstream cause. If elevated triglycerides and reactive hypoglycemia are also in your picture, the HFI page is worth reading before you accept that the standard workup has found everything there is to find.

I'm not a doctor. I'm not telling you to change your medication.

Sources

• Ludwig J, et al. (1980) — Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proceedings. PMID: 7382552 — PubMed

• Chalasani N, et al. (2018) — The diagnosis and management of nonalcoholic fatty liver disease. Hepatology. PMID: 28714183 — PubMed

• Younossi ZM, et al. (2016) — Global epidemiology of nonalcoholic fatty liver disease. Hepatology. PMID: 26707365 — PubMed

• Staufer K, Stauber RE (2023) — NAFLD renamed MASLD. Journal of Clinical Medicine. — PubMed

• Loomba R, Sanyal AJ (2013) — The global NAFLD epidemic. Nature Reviews Gastroenterology & Hepatology. PMID: 23958599 — PubMed

• Bugianesi E, et al. (2002) — Expanding the natural history of nonalcoholic steatohepatitis. American Journal of Gastroenterology. PMID: 12358255 — PubMed

• Graversen KB, et al. (2017) — Rosacea and non-alcoholic fatty liver disease. Journal of the American Academy of Dermatology. PMID: 28807527 — PubMed

• Bray GA, Nielsen SJ, Popkin BM (2004) — Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. American Journal of Clinical Nutrition. PMID: 15051594 — PubMed